Table 1 Demographic characteristics and laboratory parameters in MCKD cohort.

From: Circulating cathepsin-S levels correlate with GFR decline and sTNFR1 and sTNFR2 levels in mice and humans

MCKD

Total (n = 421)

CKD 0° (n = 69, 16.4%)

CKD I° (n = 37, 8.8%)

CKD II° (n = 68, 16.2%)

CKD III° (n = 126, 29.9%)

CKD IV° (n = 80, 19.0%)

CKD V° (n = 41, 9.7%)

Age (years, SD)

56.8 (±16.4)

49.1(±15.1)

41.6 (±14.9)

52.3 (±14.3)

63.8 (±13.6)

62.2 (±16.2)

59.1 (±14.9)

Gender (male, %)

246 (58.4)

29 (42.0)

19 (51.4)

39 (57.4)

80 (63.5)

52 (65.0)

27 (65.9)

BMI (kg/m2, SD)

26.9 (±5.7)

25.0 ± 6.0

26.1 (±5.6)

26.6 (±5.6)

26.9 (±5.0)

27.6 (±6.0)

28.5 (±6.1)

Diabetes mellitus (n, %)

96 (22.8)

5 (7.2)

3 (8.1)

8 (11.8)

30 (23.8)

29 (36.3)

21 (29.3)

Antidiabetic medication (n, %)

72 (17.1)

5 (7.2)

3 (8.1)

5 (7.4)

28 (22.2)

22 (27.5)

9 (22.0)

Arterial hypertension (n, %)

277 (65.8)

13 (18.8)

21 (56.8)

39 (57.4)

99 (78.6)

66 (82.5)

39 (95.1)

Systolic blood pressure (mmHg, SD)

137.5 (±20.1)

135.7 (±20.4)

137.1 ± 20.6

133.5 (±17.8)

136.1 (±19.9)

140.9 (±18.1)

144.0 (±25.6)

Diastolic blood pressure (mmHg, SD)

82.8 (±12.3)

83.1 (±10.9)

86.4 ± 11.8

82.7 (±11.7)

82.7 (±12.4)

81.1 (±13.5)

82.8 (±12.0)

Antihypertensive medication (n)

320

13

26

55

114

72

40

Cardiovascular disease (n, %)

56 (13.3)

2 (2.9)

2 (5.4)

4 (5.9)

22 (17.5)

18 (22.5)

8 (19.5)

Creatinine (mg/dl, SD)

2.0 (±1.7)

0.9 (±0.2)

1.0 (±0.3)

1.3 (±0.3)

1.7 (±0.4)

2.8 (±0.8)

6.0 (±2.6)

Cystatin C (mg/l, SD)

1.53 (±0.96)

0.65 (±0.17)

0.58 (±0.18)

0.91 (0.16)

1.44 (±0.29)

2.41 (±0.50)

3.52 ±0.63)

BUN (mg/dl, SD)

29.8 (±17.9)

13.5 (±3.8)

14.8 (±4.8)

19.3 (±5.2)

27.3 (±9.2)

43.1 (±12.7)

63.9 (±16.8)

eGFR (ml/min/1.73 m2 BSA, SD)

57.9 (±37.2)

108.2 (±21.8)

113.1 (±20.5)

73.1 (±8.7)

43.6 (±8.4)

22.6 (±4.6)

11.5 (±3.0)

Cathepsin-S, (ng/ml, SD)

12.5 (±5.0)

10.8 (±4.1)

11.2 (±8.5)

11.6 (±4.1)

12.9 (±4.4)

14.0 (±5.3)

13.5 (±3.8)

sTNFR1 (ng/ml, SD)

1.94 (±2.07)

0.67 (±0.62)

0.52 (±0.59)

0.83 (±0.57)

1.51 (±0.93)

3.44 (±1.74)

5.59 (±3.03)

sTNFR2 (ng/ml, SD)

11.6 (±16.7)

7.1 (±23.3)

4.5 (±2.8)

5.3 (±3.1)

10.3 (±13.8)

20.2 (±21.0)

23.4 (±7.9)

CRP (mg/dl, SD)

0.7 (±1.6)

0.3 (±0.4)

0.2 (±0.3)

0.5 (±1.0)

0.7 (±1.4)

1.1 (±2.1)

1.4 (±2.8)

Protein/creatinine ratio (mg/g, SD)

872.6 (±1697.9)

59.6 (±63.1)

827.3 (±1523.1)

474.2 (±809.7)

643.3 (±1164.7)

1875.4 (±2791.4)

2143.3 (±1609.9)

Underlying disease

None (n, %)

69 (16.4)

69 (100)

—

—

—

—

—

Diabetic nephropathy (n, %)

26 (6.2)

—

0 (0)

1 (1.5)

10 (7.9)

9 (11.3)

6 (14.6)

Hypertensive nephropathy (n, %)

58 (13.8)

—

4 (10.8)

7 (10.3)

16 (12.7)

19 (23.8)

12 (29.3)

Glomerulonephritis (n, %)

112 (26.6)

—

17 (45.9)

26 (38.2)

39 (31.0)

22 (27.5)

8 (19.5)

Polycystic kidney disease (n, %)

15 (3.6)

—

4 (10.8)

3 (4.4)

4 (3.2)

2 (2.5)

2 (4.9)

Postrenal failure (n, %)

29 (6.9)

—

1 (2.7)

9 (13.2)

13 (10.3)

4 (5.0)

2 (4.9)

Others/unknown (n, %)

112 (26.6)

—

11 (29.7)

22 (32.4)

44 (34.9)

24 (30.0)

11 (26.8)

  1. Data are presented as mean ± standard deviation or as absolute numbers (n) with percentage (%) in brackets; CKD = chronic kidney disease; BMI = body mass index; BUN = blood-urea nitrogen; eGFR calculated from CKD-EPIcreatinine-cystatin c formula; BSA = body surface area; sTNFR = soluble tumor-necrosis-factor receptor; CRP = c-reactive protein; protein/creatinine ratio in urine; antihypertensive medication also includes ACE-inhibitors/AT1-receptor antagonists, which also might have been used for solely antihypertensive medication; therefore, the number of patients with antihyperrtensive medication exceeds the number of patients with arterial hypertension in CKD groups.
Back to article page